Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Logan

Showing results (351-360 of 372) with videos related to

Pageof 38
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 21, 2014
Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012M van Gent, C J Heuvelman, H G van der Heide, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2Anju Wadhwa, Haley Johnson, Kondapa Naidu Bobba, et al.
Research Square|November 24, 2025
Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2Anju Wadhwa, Haley Johnson, Kondapa Naidu Bobba, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
International Journal of Environmental Research and Public Health|October 23, 2021
Project Earthrise: Proceedings of the Ninth Annual Conference of <i>in</i>VIVO Planetary HealthSusan L Prescott, Ganesa Wegienka, Remco Kort, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Physical Review Letters|March 28, 2015
Pedestal bifurcation and resonant field penetration at the threshold of edge-localized mode suppression in the DIII-D TokamakR Nazikian, C Paz-Soldan, J D Callen, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 38

Showing results (351-360 of 372) with videos related to

Sort By:
Pageof 38
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 21, 2014
Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012M van Gent, C J Heuvelman, H G van der Heide, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2Anju Wadhwa, Haley Johnson, Kondapa Naidu Bobba, et al.
Research Square|November 24, 2025
Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2Anju Wadhwa, Haley Johnson, Kondapa Naidu Bobba, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
International Journal of Environmental Research and Public Health|October 23, 2021
Project Earthrise: Proceedings of the Ninth Annual Conference of <i>in</i>VIVO Planetary HealthSusan L Prescott, Ganesa Wegienka, Remco Kort, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Physical Review Letters|March 28, 2015
Pedestal bifurcation and resonant field penetration at the threshold of edge-localized mode suppression in the DIII-D TokamakR Nazikian, C Paz-Soldan, J D Callen, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 38